StockData
Schrodinger, Inc. logo

Schrodinger, Inc. (SDGR) stock

SDGRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 11/3044% above fair value
$25.66−1.70 (-6.21%)

Close on Nov 17, 2026Market cap $1.92BP/E –Yield –

Schrodinger operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Schrodinger's operating income for the twelve months ending Jun 30, 2026 was -$153.45M. For fiscal 2025 it was -$166.90M. The highest annual figure on record is -$38.72M in fiscal 2019.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$166.90M–
FY2024Dec 31, 2024-$209.30M–
FY2023Dec 31, 2023-$177.45M–
FY2022Dec 31, 2022-$146.82M–
FY2021Dec 31, 2021-$111.44M–
FY2020Dec 31, 2020-$60.92M–
FY2019Dec 31, 2019-$38.72M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$41.55M–
Q1 FY2026Mar 31, 2026-$48.79M–
Q4 FY2025Dec 31, 2025-$17.16M–
Q3 FY2025Sep 30, 2025-$45.95M–
Q2 FY2025Jun 30, 2025-$52.90M–
Q1 FY2025Mar 31, 2025-$50.89M–
Q4 FY2024Dec 31, 2024-$20.71M–
Q3 FY2024Sep 30, 2024-$68.42M–
Q2 FY2024Jun 30, 2024-$52.73M–
Q1 FY2024Mar 31, 2024-$67.43M–
Q4 FY2023Dec 31, 2023-$29.62M–
Q3 FY2023Sep 30, 2023-$56.19M–
Q2 FY2023Jun 30, 2023-$61.13M–
Q1 FY2023Mar 31, 2023-$30.50M–
Q4 FY2022Dec 31, 2022-$28.54M–
Q3 FY2022Sep 30, 2022-$46.16M–
Q2 FY2022Jun 30, 2022-$43.47M–
Q1 FY2022Mar 31, 2022-$28.64M–
Q4 FY2021Dec 31, 2021-$22.52M–
Q3 FY2021Sep 30, 2021-$34.67M–
Q2 FY2021Jun 30, 2021-$30.34M–
Q1 FY2021Mar 31, 2021-$23.91M–
Q4 FY2020Dec 31, 2020-$16.58M–
Q3 FY2020Sep 30, 2020-$15.45M–
Q2 FY2020Jun 30, 2020-$17.09M–
Q1 FY2020Mar 31, 2020-$11.80M–
Q4 FY2019Dec 31, 2019-$7.85M–
Q3 FY2019Sep 30, 2019-$11.29M–
Q2 FY2019Jun 30, 2019-$13.96M–
Q1 FY2019Mar 31, 2019-$5.61M–

More Schrodinger figures

See a number that looks wrong?